Time from melanoma diagnosis to surgery is commonly delayed in Medicare patients
the ONA take:
Surgery is delayed in 1 in 5 Medicare patients with melanoma, according to a Yale study. Melanoma is the leading cause of new cancer diagnoses in the United States.
In this population-based analysis of delay of surgery among Medicare patients with melanoma, culled from the Surveillance, Epidemiology, and End Result-Medicare database, the researchers reviewed more than 32,000 cases of melanoma diagnosis in Medicare patients.
No gold standard exists on time from diagnosis to study; however, the recommended timeframe from between diagnosis and surgery is less than 6 weeks.
This study found that 22% of patients waited longer than 1.5 months for surgery, and surgery was delayed more than 3 months in 8% of patients. Delays were most common when the treating clinician was not a dermatologist (eg, a primary care physician or general surgeon).
In addition, study findings revealed a significant difference in timing from melanoma diagnosis to surgery for Medicare patients.
The researchers suggest further studies should seek to identify reasons for the delay to surgery and to consider how coordination between care providers can be improved.
Surgery is delayed in 1 in 5 Medicare patients with melanoma.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|